Gelion PLC ((GB:GELN)) has held its Q2 earnings call. Read on for the main highlights of the call.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gelion’s latest earnings call struck an optimistic tone, with management emphasizing strong technical progress and improving financial discipline despite lingering execution risks. Leaders highlighted advances in lithium‑sulfur technology, scaled-up production capacity and extended grant backing, arguing these gains outweigh partner disruptions and the long road to material commercial revenues.
Revenue Growth and Improved Profitability Metrics
Total income rose from GBP 0.4m to GBP 0.5m, a roughly 25% increase largely powered by higher grant income from programs such as ARENA and APC/ARMD4. Adjusted EBITDA loss narrowed to GBP 2.4m from GBP 2.9m, reflecting tighter cost control and more effective capture of non‑dilutive funding.
Advances in Pouch Cell Prototyping
TDK successfully produced initial Nano‑Encapsulated Sulfur pouch cells, with performance broadly in line with Gelion’s expectations. In parallel, QinetiQ manufactured Gen‑3 power cells, supported by a working material transfer pipeline between Gelion’s Australian and U.K. teams to accelerate joint prototyping.
Scaling Cathode Active Material Production
Gelion reported a major step-up in cathode active material aerial capacity, moving from 1.5Q to 4Q – its commercial high‑energy‑density target. This roughly 167% scale increase marks a key milestone in moving from prototype quantities toward production levels suitable for market‑ready lithium‑sulfur applications.
Expanded Grant Support and Targeted CapEx
ARENA project funding was lifted from GBP 4.8m to GBP 5.3m, giving Gelion about 10% more support to advance its technology programs. The company plans GBP 0.9m of equipment investment to scale production, with roughly GBP 0.4m covered by grants and GBP 0.5m funded directly, underscoring disciplined, leveraged capital allocation.
IP Pipeline and Strategic Partnerships Deepen
Gelion continued to file patents around its Nano‑Encapsulated Sulfur platform while broadening its advisory bench with figures such as Professor Rachid Yazami. Strategic collaborations span TDK, QinetiQ, leading research bodies including the Max Planck Institute and Oxford, and government‑backed entities like ARENA and the Faraday Institution.
Progress Across Integration and Recycling Units
The Integration division has built a substantial project pipeline, although management stressed that sales cycles are long and complex. In Recycling, bench‑scale validation showed the process can recover lithium and fluorine into a safer alloy form, supporting a commercial concept now being prepared for larger‑scale testing.
Balance Sheet Strength and Capital Discipline
Management pointed to a stronger balance sheet following a recent fundraising that brought in institutional investors, improving financing flexibility. The company remains focused on maximising government grants and other non‑dilutive sources while concentrating investment on U.S. expansion and near‑term commercialization paths.
Delayed Integration Revenues and Sales Cycle Reality
Despite pipeline progress, Gelion does not expect the Integration division to generate revenue in 2026 due to extended customer decision timelines. Management now targets 2027 and beyond for meaningful income from this business, signalling investors should view it as a longer‑dated option rather than a near‑term earnings driver.
Ionblox Disruption Highlights Partner Risk
The company acknowledged a setback around its Ionblox joint development arrangement after that partner ran into customer‑related problems. Gelion is continuing related technical work independently but will not advance via Ionblox, introducing some transition risk as it reshapes this collaboration pathway.
Manufacturing Yield and Technical Hurdles Ahead
Current NES prototype production is technically viable but still needs process engineering to improve yields and material utilisation to reach attractive commercial economics. Management also noted that full‑cell calendar life results are not yet complete and solid‑state separator densification and integration remain under active de‑risking.
Timeline and Competitive Market Pressures
Key milestones, including demonstrating a lithium‑sulfur cell with required performance at a major industry expo in September, are framed as targets rather than certainties. Leadership stressed that Gelion operates in a crowded, high‑risk battery space where success will depend on achieving application‑level adoption over mature incumbent chemistries.
Guidance: 2026 as a ‘Make and Market’ Year
Management framed 2026 as the year to scale and commercialise NES cathode material within a cathode market expected to grow from roughly $44bn today to as much as $150bn by 2032. Plans include deploying GBP 0.9m of scaling CapEx, leveraging extended ARENA funding, delivering CAM at commercial density to partners, advancing recycling to pilot scale and expanding in key regions while expecting no Integration revenue before 2027.
Gelion’s earnings call painted a picture of a technology company closing in on commercial relevance, with improving financial metrics and stronger partnerships underpinning its narrative. Investors will need patience as technical validation, yield gains and partner transitions play out, but the company argues that the potential reward in next‑generation cathode materials justifies the elevated risk profile.